23-07-2019
panuwach / Shutterstock.com
Merck KGaA-owned Sigma-Aldrich has petitioned the US Patent and Trademark Office (USPTO) to open an interference proceeding between its own pending CRISPR-Cas9 patents and patents awarded to the University of California, Berkeley (UC Berkeley).
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Sigma-Aldrich, Merck KGaA, USPTO, CRISPR, Broad Institute, UC Berkeley, MIT, Harvard, Cas9, patent, genome editing
Merck KGaA secures second US CRISPR patent
09-04-2020
Merck KGaA secures CRISPR patents in Japan and Singapore
27-11-2019
Merck and Evotec strike CRISPR licensing deal
14-11-2019
Broad hits out at UC Berkeley in latest CRISPR battle
02-08-2019
USPTO revives fight over CRISPR patents
27-06-2019
Federal Circuit sides with Broad Institute in CRISPR clash
11-09-2018
